Optimizing the management of benign prostatic hyperplasia

被引:13
作者
Elterman, Dean S. [4 ,5 ]
Barkin, Jack [1 ,2 ,3 ]
Kaplan, Steven A. [4 ]
机构
[1] Humber River Reg Hosp, Toronto, ON, Canada
[2] Univ Toronto, Dept Surg, Toronto, ON, Canada
[3] Can Am HIFU, Toronto, ON M6A 3B5, Canada
[4] Cornell Univ, Weill Cornell Med Coll, New York, NY USA
[5] Mem Sloan Kettering Canc Ctr, New York, NY USA
关键词
benign prostatic hyperplasia; LUTS; anticholinergics; alpha-blockers; 5-alpha-reducinhibitors;
D O I
10.1177/1756287212437361
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
One of the challenges facing primary care physicians and specialists as the population ages is the management of lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH). While as many as 18% of men in their 40s report bother from an enlarged prostate, that figure rises dramatically, whereby 50% of men in their 50s and 90% of men in their 90s will complain of bothersome symptoms related to an enlarged prostate. Studies have shown that BPH is a progressive disease, which if left untreated can result in worsening of symptoms, acute urinary retention and renal failure. Until about 20 years ago the only management option available to urologists was surgery. In the early 1990s medical therapy emerged as the predominant treatment for BPH. Therapy may be tailored to target symptoms and progression of disease.
引用
收藏
页码:77 / 83
页数:7
相关论文
共 30 条
[1]   Safety and tolerability of tolterodine for the treatment of overactive bladder in men with bladder outlet obstruction [J].
Abrams, P ;
Kaplan, S ;
Gans, HJD ;
Millard, R .
JOURNAL OF UROLOGY, 2006, 175 (03) :999-1004
[2]   Evaluation and Treatment of Lower Urinary Tract Symptoms in Older Men [J].
Abrams, P. ;
Chapple, C. ;
Khoury, S. ;
Roehrborn, C. ;
de la Rosette, J. .
JOURNAL OF UROLOGY, 2009, 181 (04) :1779-1787
[3]   Antimuscarinic Mechanisms and the Overactive Detrusor: An Update [J].
Andersson, Karl-Erik .
EUROPEAN UROLOGY, 2011, 59 (03) :377-386
[4]   Alpha-blocker therapy can be withdrawn in the majority of men following initial combination therapy with the dual 5α-reductase inhibitor dutasteride [J].
Barkin, J ;
Guimaraes, M ;
Jacobi, G ;
Pushkar, D ;
Taylor, S ;
van Vierssen Trip, OB .
EUROPEAN UROLOGY, 2003, 44 (04) :461-466
[5]   Review of dutasteride/tamsulosin fixed-dose combination for the treatment of benign prostatic hyperplasia: efficacy, safety, and patient acceptability [J].
Barkin, Jack .
PATIENT PREFERENCE AND ADHERENCE, 2011, 5 :483-490
[6]  
Barkin J, 2011, CAN J UROL, V18, P14
[7]   Effect of dutasteride, tamsulosin and the combination on patient-reported quality of life and treatment satisfaction in men with moderate-to-severe benign prostatic hyperplasia: 2-year data from the CombAT trial [J].
Barkin, Jack ;
Roehrborn, Claus G. ;
Siami, Paul ;
Haillot, Olivier ;
Morrill, Betsy ;
Black, Libby ;
Montorsi, Francesco .
BJU INTERNATIONAL, 2009, 103 (07) :919-926
[8]   BENIGN PROSTATIC HYPERPLASIA SPECIFIC HEALTH-STATUS MEASURES IN CLINICAL RESEARCH - HOW MUCH CHANGE IN THE AMERICAN-UROLOGICAL-ASSOCIATION SYMPTOM INDEX AND THE BENIGN PROSTATIC HYPERPLASIA IMPACT INDEX IS PERCEPTIBLE TO PATIENTS [J].
BARRY, MJ ;
WILLIFORD, WO ;
CHANG, YC ;
MACHI, M ;
JONES, KM ;
WALKERCORKERY, E ;
LEPOR, H .
JOURNAL OF UROLOGY, 1995, 154 (05) :1770-1774
[9]   Etiology, Epidemiology, and Natural History [J].
Bushman, Wade .
UROLOGIC CLINICS OF NORTH AMERICA, 2009, 36 (04) :403-+
[10]   Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5α-reductase inhibitor [J].
Clark, RV ;
Hermann, DJ ;
Cunningham, GR ;
Wilson, TH ;
Morrill, BB ;
Hobbs, S .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2004, 89 (05) :2179-2184